


Figure S1: Clinical Study Subject Disposition



	Placebo+Metformin	Abemaciclib+Metformin	Placebo+Iohexol	Abemaciclib+Iohexol
Subjects with evaluable safety data (subjects dosed)	N = 33 ^a	N = 35 ^b	N = 32	N = 33
Subjects with evaluable PK data (including emesis)	N = 30 ^c	N = 32 ^d	N = 32	N = 33
Subjects with evaluable PK data (excluding emesis)	N = 30	N = 28 ^e	N = 32	N = 30 ^f

Abbreviations: PK = pharmacokinetic; N = number of subjects

^a. Includes Subjects 01001 and 01007 (dosing error – received metformin only)

^b. Includes Subject 01004 and 01005 (dosing error – received metformin only)

^c. Excludes Subjects 01001, 01007 (dosing error), and 01010 (large sampling time deviations)

^d. Excludes Subjects 01004, 01005 (dosing error), and 01031 (anomalous PK profile)

^e. Excludes Subjects 01018, 01021, 02001, and 02007 (emesis)

^f. Excludes Subjects 01021, 02001, and 02007 (emesis)